David S. Wolpa Counsel

Experience

• Representation of Newbridge Securities Corporation, as sole book-running manager and as placement agent, in connection with a $9.4 million public offering and concurrent private placement of common stock and warrants by Gain Therapeutics, Inc. (Nasdaq: GANX), a clinical-stage biotech company leading the discovery and development of next generation allosteric therapies.
• Representation of ThinkEquity, as underwriter, in connection with an approximate $8.5 million follow-on public offering of common stock and pre-funded warrants by TransCode Therapeutics, Inc. (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics.
• Representation of Journey Medical Corporation (Nasdaq: DERM), commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, in connection with the establishment of an at-the-market program for the offering of common stock.
• Representation of a privately held clinical-stage biopharmaceutical company in the private placement of convertible preferred stock.
• Representation of Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, in a registered direct offering and concurrent private placement.
• Representation of Avenue Therapeutics, Inc. (Nasdaq: ATXI), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, in a $12 million follow-on public offering of units consisting of common stock (or pre-funded warrants) and warrants.
• Representation of a not-for-profit, member-owned credit union in its $200 million private offering of subordinated notes.
• Representation of Direct Digital Holdings Inc. (Nasdaq: DRCT), an end-to-end full-service digital advertising platform, in its $15.4 million initial public offering of Class A common stock.
• Representation of The Benchmark Company, as lead book-running manager, in connection with the $15 million initial public offering of ordinary shares by FGI Industries Ltd. (Nasdaq: FGI), a leading global supplier of kitchen and bath products.
• Representation of Alliance Global Partners, an investment and advisory firm, as sole book-running manager, in connection with a $10 million public offering of common stock by Enveric Biosciences (Nasdaq: ENVB), an innovative biotechnology company developing next-generation mental health and oncology treatments and clinical discovery platform.
• Representation of  Alliance Global Partners, an investment and advisory firm, as exclusive placement agent, in connection with a $7 million registered direct offering of common stock by Tanzanian Gold Corp. (TSX: TNX, NYSE: TRX), a company engaged in the exploration and development of mineral property interests in the United Republic of Tanzania.
• Representation of B. Riley Securities, Inc., as representative of several underwriters, in a $35 million initial public offering of common stock by Journey Medical Corporation (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions.
• Representation of B. Riley Securities, Inc., as representative of several underwriters, in a $45.2 million initial public offering of common stock by Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
• Representation of ThinkEquity, a division of Fordham Financial Management Inc., as underwriter in a $28.75 million initial public offering of common stock by TransCode Therapeutics Inc. (Nasdaq: RNAZ), an emerging RNA oncology company.
• Representation of Teledyne Technologies, Inc. (NYSE: TDY), a leading provider
  of sophisticated electronic components, instruments and communications products,
  in its $8 billion acquisition of FLIR Systems, Inc. (Nasdaq: FLIR), a
  world-leading industrial technology company focused on intelligent sensing
  solutions for defense and industrial applications.
• Representation of ThinkEquity, as representative of the several underwriters,
  in the $25 million initial public offering by TransCode Therapeutics, Inc.
  (Nasdaq: RNAZ), an emerging RNA oncology company created on the belief that
  cancer can be defeated through the intelligent design and effective delivery of
  RNA therapeutics.
• Representation of Cleveland BioLabs, Inc. (Nasdaq: CBLI), an innovative
  biopharmaceutical company developing novel approaches to activate the immune
  system and address serious medical needs, in its merger with Cytocom Inc., a
  private a clinical-stage biopharmaceutical company developing novel
  immunotherapies targeting autoimmune, inflammatory, infectious diseases and
  cancers based on a proprietary, multi receptor platform, or the AIMS platform,
  designed to rebalance the body’s immune system and restore homeostasis.
• Representation of Stifel, Nicolaus & Company, as representative of several underwriters, in a $63 million initial public offering of common stock by Karat Packaging Inc. (Nasdaq: KRT), a rapidly-growing specialty distributor and select manufacturer of environmentally-friendly disposable foodservice products and related items.
• Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private of and sale of convertible promissory notes and warrants by Ordergroove, Inc., the operator of an e-commerce platform for retailers.
• Representation of National Securities Corp., acting as exclusive placement agent, in connection with a private offering and sale of preferred stock by Cyprium Therapeutics, Inc.,  a clinical-stage biopharmaceutical company.
• Representation of National Securities Corp., acting as sole book-running manager, in connection with a public offering and sale of common stock by Super League Gaming, a company that brings live and digital e-sports entertainment experiences directly to competitive gamers.
• Representation of  B. Riley FBR, Inc. (formerly FBR Capital Markets & Co.) as placement agent in connection with the extension of its existing relationship with Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company.
• Representation of Alliance Global Partners (AGP), a regional investment and advisory firm providing investment advisory and brokerage services to individuals and institutions, in connection with the launch of an at-the-market program in which AGP serves as placement agent to ProPhase Labs, Inc. (Nasdaq: PRPH), a manufacturing and marketing company with experience with OTC consumer healthcare products and dietary supplements.
• Representation of Pareteum Corporation (Nasdaq: TEUM), a global cloud communications platform company, in its issuance of $17.5 million in senior secured convertible notes, with warrants, to an institutional investor.
• Representation of a publicly traded innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs in its $3.175 million at-the-market registered direct offering of common stock.
• Representation of ThinkEquity, as representative of the several underwriters, in the initial public offering by LMP Automotive Holdings Inc. (Nasdsq: LMPX), an e-commerce and facilities-based platform where users can buy, sell and rent new and used automobiles.
• Representation of ThinkEquity, as sole book-running manager, in the $19.2 million follow-on equity offering by LMP Automotive Holdings Inc. (Nasdsq: LMPX), an e-commerce and facilities-based platform where users can buy, sell and rent new and used automobiles.
• Representation of Speedway Motorsports, Inc. (NYSE:TRK), a leading marketer and promotor of motorsports entertainment, in its public company “going private” 2-step tender offer and merger transaction with Sonic Financial Corporation and O. Bruton Smith and his family, in a transaction valued at over $265 million.
• Representation of JMP Securities, initial purchaser and placement agent, in connection with a concurrent $30 million Rule 144A convertible debt and $9.5 million private placement (PIPE) of Class B Common Stock of RumbleOn, Inc. (Nasdaq: RMBL).
• Representation of National Securities Corp., lead book-running manager, and Craig-Hallum Capital Group, joint book-running manager, in a $7.5 million underwritten public offering of Class B Common Stock of RumbleOn, Inc. (Nasdaq: RMBL).
• Representation of National Securities Corp. and Craig-Hallum Capital Group as placement agents in connection with a $21.6 million private placement (PIPE) of Class B common stock by RumbleOn, Inc. (Nasdaq: RMBL).
• Representation of National Securities Corp. as underwriter in connection with an underwritten public offering of Class B Common Stock by RumbleOn Inc. (Nasdaq: RMBL).
• Representation as underwriters’ counsel of National Securities Corp., as representative of the underwriting syndicate, in connection with a follow-on public offering of common stock by Checkpoint Therapeutics, Inc. (Nasdaq: CKPT), a clinical-stage immune-oncology biopharmaceutical company.